Compare Jabil Inc (JBL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Jabil Inc trades at $319 (market cap $32.06B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.8× Jabil Inc's market cap, and Jabil Inc pays a 0.1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| JBL | VRTX | |
|---|---|---|
Market Cap | $32.06B | $121.95B |
Sector | Technology | Health |
52-Week High | $385.50 | $529.59 |
52-Week Low | $192.49 | $366.54 |
Enterprise Value | $34.59B | $116.69B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.91, up 1.63% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 50% analyst buy ratings and a $448.29 consensus price target, representing 46% upside potential. Recent news highlights AI infrastructure growth and new logistics hub expansion in Penang, while technical indicators show oversold conditions with RSI at 17.67.
The outlook remains positive with AI-driven revenue growth accelerating, though valuation at 38.29 P/E appears stretched. Key risks include competitive pressures in EMS sector and execution challenges in scaling AI manufacturing capacity. The stock offers growth exposure to AI infrastructure boom but requires monitoring of margin sustainability.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
